Immunoassay Market By Type (Radioimmunoassay (RIA), Enzyme Immunoassays (EIA), Fluoroimmnoassay (FIA) Chemiluminescence immunoassay (CLIA) and Others), By Application (Disease Diagnosis, Therapeutic Drug Monitoring, Drug Discovery, Clinical Chemistry, Hematology, and Others), By End User (Hospitals, Pharma & Biotech Companies, Clinical Laboratories and Others), and Geography


Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Immunoassay market size was valued at USD 36,456.9 million in 2021 and is expected to grow at a CAGR of 5.1% from 2022 to 2028. The increasing prevalence of acute and chronic infectious diseases, the rising geriatric population, growing awareness for early disease diagnosis, technological advancements in immunoassays, increasing use of immunoassays in precision oncology and drug & alcohol testing, and the emergence of COVID-19 are driving the immunoassay market. Antibodies bind to antigens in immunoassay tests, which allows users to detect and analyze specific chemicals. Immunoassays are a type of test that can be used to diagnose disease. Additionally, test findings can reveal information about an illness that can aid in therapy planning (for example, when estrogenic receptors are measured in breast cancer). Enzyme Immunoassay had a market revenue share of 37.3% in 2021, and it is expected to grow at a CAGR of 4.9% from 2022 to 2028. It has a number of advantages; the main advantage of enzyme immunoassay over immunodiffusion or immunoelectrophoresis procedures is reduced assay time. Disease diagnosis is expected to have an xx percent market revenue share from 2022 to 2028. However, the Immunoassay market is hampered by Stringent Regulatory Requirements for the Approval of Immunoassay Instruments and Consumables. Key Developments: In October 2020, Thermo Fisher Scientific launched its EliA SARS-CoV-2-Sp1 IgG test and OmniPATH COVID-19 Total Antibody ELISA test, for the diagnosis of COVID-19 antibodies In January 2021, Abbott received the CE Mark for its Panbio COVID-19 Ag Rapid Test Device for the asymptomatic diagnosis of the SARS-CoV-2 virus. It also offers self-swabbing In December 2020, Beckman Coulter, part of Danaher (US) company, launched the first high-quality and throughput assay, called Access SARS-CoV-2 Antigen assay, for the COVID-19 antigen diagnosis, in the US

Immunoassay Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

Immunoassay Market Growth

The immunoassay market is surging owing to frequent acquisitions and launchings by the market players. Strategic alliances by the players, such as acquisitions, mergers, expansions, and new product launches, may enhance the company’s growth.

Key Features of the Reports

  • The immunoassay market report provides granular level information about the market size, regional market share, historic market (2015 to 2020) and forecast (2021 to 2027)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Immunoassay Market Segmentation

By Product Type
  • Radioimmunoassay (RIA)
  • Enzyme Immunoassays (EIA)
  • Fluoroimmnoassay (FIA)
  • Chemiluminescenceimmunoassay (CLIA)
  • Others
By Application
  • Disease Diagnosis
  • Therapeutic Drug Monitoring
  • Drug Discovery
  • Clinical Chemistry
  • Hematology
  • Others
End User
  • Hospitals
  • Pharma & Biotech Companies
  • Clinical Laboratories
  • Others

Frequently Asked Questions

The immunoassay market is projected to expand at a CAGR of 5.1% during the forecast period.

Bio-Rad Laboratories Inc., Thermo Fisher Scientific , EMD Millipore (Merck KGaA., Becton, Dickinson and Company., Microsynth AG, Quansys Biosciences Inc , QIAGEN N.V., Hoffmann-La Roche Ltd.

North America is dominating the immunoassay market

  • Bio-Rad Laboratories Inc.
  • Thermo Fisher Scientific
  • EMD Millipore (Merck KGaA.
  • Becton, Dickinson and Company.
  • Microsynth AG
  • Quansys Biosciences Inc
  • Hoffmann-La Roche Ltd.
  • Danaher Corporation.
  • Luminex Corporation